Slam Bio is a biotech company developing a platform of very promising first-in-class human antibody-drug conjugates (ADCs) and bispecific monoclonal antibodies targeting the most challenging blood cancer (MDS, AML, CTCL and FL). SLAM Bio’s lead asset SLM124 demonstrate a profound activity against these cancers in preclinical models. The lead asset will be in the clinic in 2026.